Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...

Obeldesivir provided faster symptom relief but did not reduce hospitalization or all-cause mortality in high-risk nonhospitalized patients with COVID-19.

From L-R, Garcia, Wahl and Battaglia Approximately 15 million to 20 million Americans who have acquired COVID-19 experience ...

The updated formula for Moderna’s COVID-19 vaccine generates a 16-fold increase in antibodies neutralize the intended SARS-CoV-2 variant.

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in ...

In a study published in the Journal of Virology, scientists demonstrate, in vitro, that by reactivating cellular defense systems hijacked by SARS-CoV-2 for its own benefit, it is possible to ...

The updated COVID-19 vaccines targeting the LP.8.1 variant have been approved by the FDA. But they may be a lot harder to get ...

In a recent study published in the Journal of Experimental Medicine, researchers identified the cellular tropism and transcriptome consequences of severe acute respiratory syndrome coronavirus 2 (SARS ...

A higher proportion of adolescents who tested positive for COVID-19 reported ongoing symptoms compared with those who tested negative or never tested.

Azelastine nasal spray was associated with a reduced risk for SARS-CoV-2 infection, according to the results of a phase 2 randomized controlled trial published in JAMA Internal Medicine.In the trial, ...

Expert consensus outlines diagnostic and therapeutic strategies for managing SARS-CoV-2 infection in solid organ transplant ...

In a recent study published in the International Journal of Molecular Sciences, researchers reported that lentiviral pseudovirions pseudotyped with severe acute respiratory syndrome coronavirus 2 ...